EI
ESPR

EAM Investors’s Esperion Therapeutics ESPR Stock Holding History

EAM Investors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-65,683
Closed -$4.75M – 309
2018
Q1 		$4.75M Buy
65,683
+3,511
+6% +$258K 0.79% 5
2017
Q4 		$4.09M Sell
62,172
-30,727
-33% -$1.65M 0.73% 11
2017
Q3 		$4.66M Sell
92,899
-7,271
-7% -$351K 0.62% 36
2017
Q2 		$4.64M Sell
100,170
-28,130
-22% -$1.03M 0.77% 11
2017
Q1 		$4.53M Buy
+128,300
New +$2.94M 0.71% 12
2015
Q2 		– Sell
-89,335
Closed -$8.27M – 335
2015
Q1 		$8.27M Sell
89,335
-94,685
-51% -$6.11M 0.96% 1
2014
Q4 		$7.44M Buy
184,020
+115,099
+167% +$3.52M 1.04% 1
2014
Q3 		$1.69M Buy
+68,921
New +$1.1M 0.34% 98

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

EAM Investors's ESPR Position: Q2 2018 in Review

EAM Investors sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 65,683 shares — an estimated $4.75M sold.

EAM Investors first reported a position in ESPR in Q3 2014 and held it in 8 quarters. The position peaked at $8.27M in Q1 2015. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • EAM Investors reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • EAM Investors sold 65,683 Esperion Therapeutics shares in Q2 2018, an estimated $4.75M.
  • EAM Investors first reported a position in Esperion Therapeutics in Q3 2014 and held it in 8 quarters.
  • EAM Investors's Esperion Therapeutics position peaked at $8.27M in Q1 2015.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on EAM Investors's 13F filing for Q2 2018, filed 3 Aug 2018.